In the SURMOUNT-4 trial, withdrawal of tirzepatide led to rapid weight regain among participants with obesity or overweight, researchers report. In those who continued the
“Comprehensive, evidence-based obesity treatment combines behavioral interventions, nutrition, physical activity, pharmacotherapy, and metabolic/bariatric procedures as appropriate for individual patients,” conclude authors of a review article.
In the SELECT trial, subcutaneous semaglutide 2.4 mg once weekly produced superior outcomes compared with placebo in patients with preexisting cardiovascular disease and overweight or
Clinicians should present weight loss treatments as positive opportunities when discussing excess weight during clinical visits rather than framing the conversation in negative terms, a
In adolescents with severe obesity, phentermine-topiramate is a cost-effective treatment at a willingness-to-pay threshold of $100,000 to $150,000 per quality-adjusted life-year (QALY), researchers report. “Further
In a scientific statement from the American Heart Association, a crosswalk of major guidelines is used to “summarize the evidence and fundamental gaps related to
A 1.5 million-participant study of incident cardiovascular disease shows that more than one-half of cases and about one-fifth of related deaths result from 5 modifiable
Authors of a review article describe how low-grade inflammation in patients with obesity plays a role in the development of other immunological diseases, including cancers
During the first year after initiation of antiretroviral therapy (ART), changes in weight and body composition are associated with “contemporaneous changes in metabolic parameters and
Orforglipron, a once-daily oral therapy under development for use in adults with obesity, was associated with weight reduction in a phase 2 trial. Adverse events